Clinical Trial

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and efficacy of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 (TRBC1/2 CAR-NK cells) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL).
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07164560
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Peking University Cancer Hospital & Institute
Conditions Refractory/Recurrent Peripheral T-cell Lymphoma
Enrollment 45 participants
Start Date 2026-04-01
Primary Completion 2029-01-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-17